- Home
- ATXS vs SGMO Comparison
ATXS vs SGMO Comparison
Compare ATXS & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- SGMO
- Stock Information
- Founded
- ATXS 2008
- SGMO 1995
- Country
- ATXS United States
- SGMO United States
- Employees
- ATXS N/A
- SGMO N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATXS Health Care
- SGMO Health Care
- Exchange
- ATXS Nasdaq
- SGMO Nasdaq
- Market Cap
- ATXS 516.4M
- SGMO 488.2M
- IPO Year
- ATXS 2015
- SGMO 2000
- Fundamental
- Price
- ATXS $7.50
- SGMO $1.09
- Analyst Decision
- ATXS Strong Buy
- SGMO Buy
- Analyst Count
- ATXS 5
- SGMO 5
- Target Price
- ATXS $25.60
- SGMO $5.20
- AVG Volume (30 Days)
- ATXS 368.6K
- SGMO 10.5M
- Earning Date
- ATXS 03-03-2025
- SGMO 03-12-2025
- Dividend Yield
- ATXS N/A
- SGMO N/A
- EPS Growth
- ATXS N/A
- SGMO N/A
- EPS
- ATXS N/A
- SGMO N/A
- Revenue
- ATXS N/A
- SGMO $52,291,000.00
- Revenue This Year
- ATXS N/A
- SGMO N/A
- Revenue Next Year
- ATXS N/A
- SGMO $5.97
- P/E Ratio
- ATXS N/A
- SGMO N/A
- Revenue Growth
- ATXS N/A
- SGMO N/A
- 52 Week Low
- ATXS $6.96
- SGMO $0.30
- 52 Week High
- ATXS $16.90
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- ATXS 29.58
- SGMO 35.59
- Support Level
- ATXS $7.29
- SGMO $1.00
- Resistance Level
- ATXS $7.95
- SGMO $1.18
- Average True Range (ATR)
- ATXS 0.42
- SGMO 0.16
- MACD
- ATXS -0.08
- SGMO -0.06
- Stochastic Oscillator
- ATXS 15.25
- SGMO 9.89
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.